A Conversation with MMS Founder and CEO Dr. Uma Sharma: Building MMS: 20 Years of People-First, Data-Led Drug Development 

Part Two of a Two-part Interview Series 

To read Part One, click here:  

As MMS marks its 20-year anniversary, founder and CEO Uma Sharma, PhD, looks back on the company’s evolution, from its early beginnings to the work it delivers today. 

In Part One, Dr. Sharma explored how she founded MMS for people, and to address a fundamental gap in how data is typically handled in clinical development. In Part Two, she reflects on the meaning of innovation, shares some of the company’s most meaningful moments of real-world impact and discusses the instrumental role culture has continued to play as the organization has grown. 

Q: Innovation is often framed as technology driven. How does MMS define innovation? 

Technology matters, but innovation isn’t a tool. It’s judgment. 

Right now, the industry is noisy. Everyone has a platform. Everyone has AI. Everyone has a dashboard. But none of that matters if it doesn’t change the quality of the decisions being made, or the strength of the evidence being brought to regulators. 

At MMS, innovation has always meant solving the problem in front of us, especially when there is no precedent. We’ve been involved in many “firsts,” from early work in rare diseases to regulatory strategies where there wasn’t a clear pathway. In those moments, innovation is not about doing something flashy. It’s about bringing scientific clarity and regulatory credibility when the rulebook doesn’t exist. 

And when something has never been done before, you can’t outsource the thinking, not to a template, not to a system, and not to technology. The work is to build a rationale that holds up scientifically, a strategy that is defensible, and a totality-of-evidence story that is coherent across endpoints, data quality, and clinical context. At MMS, we have many firsts to our credit thanks to our global teams who have a “can do” mindset along with the highest scientific integrity.  

That same philosophy is what shaped our acquisition of Exploristics, which strengthens our ability to support adaptive and Bayesian trial designs. Not because “Bayesian” sounds modern, but because smarter design can reduce waste, preserve patients, and get to an answer faster. If a traditional design didn’t work the first time, repeating it without learning isn’t persistence, it’s inefficiency. Better assumptions, better sample size decisions, and more intentional interim strategies can materially change outcomes, especially when paired with the right regulatory engagement and purpose-built technology like KerusCloud ® and Datacise ®. 

That’s how we define innovation: not noise, not novelty, but progress that stands up to scrutiny. 

Q: MMS works across large pharma and emerging biotech. What does that say about your impact? 

It signals trust. Large pharma doesn’t choose partners casually. They have options, they have scale, and they have internal expertise. When they bring MMS in, it’s because they want a team that can operate at the level of rigor, accountability, and regulatory discipline required to deliver under scrutiny, especially in high-stakes end-game moments like submissions, complex analyses, and critical agency interactions. 

At the same time, emerging biotech work with MMS because they need that same level of scientific depth, but with urgency and practicality. They can’t afford wasted cycles, unclear answers, or partners who hide behind process. They need teams that can think, move, and execute with precision. 

One moment that stands out is our role in supporting two of the three early approved COVID-19 treatments. That was a global crisis with no precedent, where every day mattered and the tolerance for error was essentially zero. 

Beyond COVID, our work across oncology and rare diseases, including pro bono support for ultra-rare conditions, reflects what drives our teams. We care about getting the science right, protecting the integrity of the evidence, and ultimately helping therapies reach patients, not just completing tasks. 

Q: How does culture factor into MMS’s ability to deliver that level of impact? 

Culture is everything, and I don’t say that as a slogan. I say it because in our industry, culture shows up in the work. It shows up in the quality of the data. It shows up in how teams respond under pressure. And it shows up in whether sponsors can trust what they’re seeing when decisions are being made. 

From the beginning, MMS was built on a simple belief: colleagues are just as important as clients. The people doing the work are the ones who make success possible. If you don’t invest in them, if you don’t respect them, if you don’t give them room to think and lead, you don’t get excellence. You get compliance. And that’s not enough in drug development. 

That people-first foundation is one of the reasons we’ve maintained unusually strong retention, even in regions and functions where turnover is typically high. And retention isn’t just an HR metric. It directly impacts sponsors. It means continuity, deeper program knowledge, fewer handoffs, fewer errors, and stronger accountability. It means the people leading your submission today aren’t learning your program for the first time; they’ve lived it. 

We’ve also intentionally protected a culture that stays open and bottom-up. Some of our best tools, processes, and innovations didn’t come from a top-down mandate. They came from colleagues who were deep in the work, seeing inefficiencies, recognizing risk early, and having the confidence and support to build something better. That’s how real operational excellence happens, through empowered experts improving the system from the inside. 

I have always believed every colleague is a mini entrepreneur inside the company. Not in the sense that everyone is doing their own thing, but in the sense that people take ownership. They think ahead. They solve problems before they become escalations. And they care about the outcome, not just their piece of the process. 

When individual goals and company goals align, momentum follows. And when that momentum is paired with scientific rigor and a genuine commitment to patients, the result is a culture that doesn’t just feel good internally; it performs. Sponsors can see it in the quality, the speed, and the confidence we bring when the work matters most. 

Our culture is one of the reasons sponsors come back to us, because they can feel the difference in how the work gets done. 

Q: Looking ahead, what excites you most about the future of MMS and the industry? 

There is still so much work to do, and I mean that in the most motivating way. 

Many diseases remain poorly understood. Drug development is still too slow, too expensive, and in too many cases, not designed around the reality of patients’ lives. We must get better at asking the right questions earlier, designing smarter studies, and making decisions based on evidence, not inertia. We also must reduce development costs and expand access globally, because scientific breakthroughs don’t matter if they never reach the people who need them. 

What excites me is that we’re entering a period where the industry can be more precise and more efficient, but only if we stay disciplined. Technology can absolutely accelerate work, but it cannot replace judgment. It cannot replace scientific integrity. And it can’t replace the hard work of building evidence that regulators can trust, and patients can benefit from. 

MMS has always been strongest in the moments where there is no clear playbook, whether that’s biosimilars, emerging therapeutic areas like psychedelics, rare and orphan conditions, or global data harmonization. When there is no map, we draw one. Others may refine it later, but progress starts with someone willing to move first, with rigor, with clarity, and with accountability. 

And as we grow, what will not change is what we were founded on: people and purpose. We will continue to build a culture where colleagues take ownership, where the best ideas can come from anywhere, and where the work is done with the level of care it deserves. Because in the end, this is not just about timelines and deliverables. It’s about getting the science right, protecting the integrity of the data, and helping therapies reach patients faster and more responsibly. 

That’s what excites me. And that’s what MMS will continue to stand for. 

About MMS Founder and CEO Dr. Uma Sharma, PhD 

For more information, visit https://mmsholdings.com/